vs
Apellis Pharmaceuticals, Inc.（APLS）与Axsome Therapeutics, Inc.（AXSM）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Axsome Therapeutics, Inc.的1.0倍（$199.9M vs $196.0M），Axsome Therapeutics, Inc.净利率更高（-14.6% vs -29.5%，领先14.9%），Axsome Therapeutics, Inc.同比增速更快（65.0% vs -5.9%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-18.7M），过去两年Axsome Therapeutics, Inc.的营收复合增速更高（61.7% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Jazz Pharmaceuticals是一家全球生物制药企业，专注于肿瘤学与神经科学领域的药物研发及商业化。公司2003年在美国加利福尼亚州成立，目前总部位于爱尔兰都柏林，业务覆盖全球多个核心市场。
APLS vs AXSM — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $196.0M |
| 净利润 | $-59.0M | $-28.6M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | -13.8% |
| 净利率 | -29.5% | -14.6% |
| 营收同比 | -5.9% | 65.0% |
| 净利润同比 | -62.2% | 61.9% |
| 每股收益（稀释后） | $-0.40 | $-0.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $196.0M | ||
| Q3 25 | $458.6M | $171.0M | ||
| Q2 25 | $178.5M | $150.0M | ||
| Q1 25 | $166.8M | $121.5M | ||
| Q4 24 | $212.5M | $118.8M | ||
| Q3 24 | $196.8M | $104.8M | ||
| Q2 24 | $199.7M | $87.2M | ||
| Q1 24 | $172.3M | $75.0M |
| Q4 25 | $-59.0M | $-28.6M | ||
| Q3 25 | $215.7M | $-47.2M | ||
| Q2 25 | $-42.2M | $-48.0M | ||
| Q1 25 | $-92.2M | $-59.4M | ||
| Q4 24 | $-36.4M | $-74.9M | ||
| Q3 24 | $-57.4M | $-64.6M | ||
| Q2 24 | $-37.7M | $-79.3M | ||
| Q1 24 | $-66.4M | $-68.4M |
| Q4 25 | -25.6% | -13.8% | ||
| Q3 25 | 48.7% | -27.0% | ||
| Q2 25 | -18.6% | -24.5% | ||
| Q1 25 | -50.0% | -46.9% | ||
| Q4 24 | -12.3% | -61.1% | ||
| Q3 24 | -24.0% | -59.8% | ||
| Q2 24 | -14.7% | -89.5% | ||
| Q1 24 | -36.0% | -89.7% |
| Q4 25 | -29.5% | -14.6% | ||
| Q3 25 | 47.0% | -27.6% | ||
| Q2 25 | -23.6% | -32.0% | ||
| Q1 25 | -55.3% | -48.9% | ||
| Q4 24 | -17.1% | -63.1% | ||
| Q3 24 | -29.2% | -61.7% | ||
| Q2 24 | -18.9% | -91.0% | ||
| Q1 24 | -38.5% | -91.1% |
| Q4 25 | $-0.40 | $-0.55 | ||
| Q3 25 | $1.67 | $-0.94 | ||
| Q2 25 | $-0.33 | $-0.97 | ||
| Q1 25 | $-0.74 | $-1.22 | ||
| Q4 24 | $-0.30 | $-1.54 | ||
| Q3 24 | $-0.46 | $-1.34 | ||
| Q2 24 | $-0.30 | $-1.67 | ||
| Q1 24 | $-0.54 | $-1.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $322.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $88.3M |
| 总资产 | $1.1B | $689.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $322.9M | ||
| Q3 25 | $479.2M | $325.3M | ||
| Q2 25 | $370.0M | $303.0M | ||
| Q1 25 | $358.4M | $300.9M | ||
| Q4 24 | $411.3M | $315.4M | ||
| Q3 24 | $396.9M | $327.3M | ||
| Q2 24 | $360.1M | $315.7M | ||
| Q1 24 | $325.9M | $331.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $88.3M | ||
| Q3 25 | $401.2M | $73.7M | ||
| Q2 25 | $156.3M | $73.1M | ||
| Q1 25 | $164.2M | $53.2M | ||
| Q4 24 | $228.5M | $57.0M | ||
| Q3 24 | $237.1M | $92.9M | ||
| Q2 24 | $264.3M | $102.9M | ||
| Q1 24 | $266.7M | $144.0M |
| Q4 25 | $1.1B | $689.8M | ||
| Q3 25 | $1.1B | $669.3M | ||
| Q2 25 | $821.4M | $639.8M | ||
| Q1 25 | $807.3M | $596.7M | ||
| Q4 24 | $885.1M | $568.5M | ||
| Q3 24 | $901.9M | $561.5M | ||
| Q2 24 | $904.5M | $548.2M | ||
| Q1 24 | $831.9M | $545.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-18.7M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-18.7M |
| 自由现金流率自由现金流/营收 | -7.1% | -9.6% |
| 资本支出强度资本支出/营收 | 0.1% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-93.9M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $-18.7M | ||
| Q3 25 | $108.5M | $1.0M | ||
| Q2 25 | $4.4M | $-32.4M | ||
| Q1 25 | $-53.4M | $-43.4M | ||
| Q4 24 | $19.4M | $-26.2M | ||
| Q3 24 | $34.1M | $-18.6M | ||
| Q2 24 | $-8.3M | $-30.1M | ||
| Q1 24 | $-133.0M | $-53.5M |
| Q4 25 | $-14.3M | $-18.7M | ||
| Q3 25 | $108.3M | $988.0K | ||
| Q2 25 | $4.4M | $-32.4M | ||
| Q1 25 | $-53.4M | $-43.7M | ||
| Q4 24 | $19.3M | $-26.2M | ||
| Q3 24 | — | $-18.7M | ||
| Q2 24 | $-8.4M | $-30.2M | ||
| Q1 24 | $-133.3M | $-53.6M |
| Q4 25 | -7.1% | -9.6% | ||
| Q3 25 | 23.6% | 0.6% | ||
| Q2 25 | 2.5% | -21.6% | ||
| Q1 25 | -32.0% | -36.0% | ||
| Q4 24 | 9.1% | -22.1% | ||
| Q3 24 | — | -17.9% | ||
| Q2 24 | -4.2% | -34.6% | ||
| Q1 24 | -77.3% | -71.4% |
| Q4 25 | 0.1% | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.0% | 0.3% | ||
| Q4 24 | 0.0% | 0.0% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | 0.0% | 0.1% | ||
| Q1 24 | 0.2% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
AXSM
暂无分部数据
